Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary-School Children in 1999-2000 and Response to a Booster: A Phase 4 Clinical Trial
KP Perrett, AP Winter, E Kibwana, C Jin, TM John, LM Yu, R Borrow, N Curtis, AJ Pollard
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2010
Financial support. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, NIHR Thames Valley Comprehensive Local Research Network, GlaxoSmithKline Vaccines, and the European Society of Paediatric Infectious Diseases. A.J.P. is a Jenner Institute Investigator.Potential conflicts of interest. The study was partly funded by GlaxoSmithKline. A.J.P. has conducted clinical trials on behalf of Oxford University sponsored by manufacturers of vaccines. A.J.P. does not accept any personal payments from vaccine manufacturers; honoraria, travel expenses, and grants for support of educational activities are paid to an educational/ administrative fund held by the Department of Paediatrics, University of Oxford. R. B. has received assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur, and Baxter Bioscience and has served as an ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur, and Baxter Bioscience. Industry honoraria received for consulting, lecturing, and writing are paid directly into the Central Manchester and Manchester Children's University Hospitals National Health Service Trust endowment fund. R. B. has performed contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals, Emergent Europe, and Merck). All other authors: no conflicts.